Curaleaf

What it is

Curaleaf Holdings Inc. is a vertically integrated cannabis company headquartered in New York that cultivates, processes, and sells cannabis and hemp-derived products through its own dispensaries and wholesale channels ^[1][2]. The company operates under state-by-state licenses in the United States and, through subsidiaries, in parts of Europe ^[2]. It trades publicly on the Toronto Stock Exchange under the ticker CURA and over-the-counter in the US as CURLF ^[1].

Within the cannabis industry, Curaleaf is categorized as a multi-state operator, or MSO — a company that holds licenses and runs operations in several US states simultaneously. Industry trade press has repeatedly described it as among the largest MSOs by revenue ^[3], though specific rankings shift quarter to quarter and should be checked against current filings rather than older articles.

Ownership and structure

Curaleaf Holdings is a publicly traded parent company; it is not privately owned by a single individual, though executive chairman Boris Jordan has historically been the largest shareholder according to company disclosures ^[1][2]. The company was assembled through a series of mergers and acquisitions, most notably the 2020 acquisition of Grassroots Cannabis, which expanded its footprint into the Midwest, and the 2020 acquisition of Select (Cura Partners), a vape and concentrate brand originally founded in Oregon ^[4][5].

Those two acquisitions are why product labels you might see at a Curaleaf-affiliated dispensary can read 'Select' or 'Grassroots' rather than 'Curaleaf' — they are house brands under the same corporate parent ^[4][5].

Market and category focus

Curaleaf's business spans cultivation, manufacturing (edibles, vapes, concentrates, tinctures, topicals), retail dispensaries, and wholesale distribution to other licensed retailers ^[2]. The Select brand is primarily known for vape cartridges and concentrates; Grassroots is known for flower and pre-rolls ^[4][5]. Curaleaf-branded products span most major form factors.

The company has also expanded into international medical cannabis markets, including Germany and the United Kingdom, through its Curaleaf International subsidiary ^[2]. In 2024 it announced it would pursue a listing on a US exchange contingent on federal regulatory changes ^[3] — readers should treat any such announcements as conditional until confirmed by filings.

Reputation, awards, and controversies

Curaleaf has received industry trade-press recognition over the years, but cannabis industry awards generally are not independently audited and should not be read as quality guarantees Weak / limited.

Verifiable issues on the record include:

• 2019 FDA warning letter. The US Food and Drug Administration issued Curaleaf a warning letter for making unsubstantiated health claims about CBD products, including claims related to cancer, Alzheimer's, opioid withdrawal, and pet anxiety ^[6]. The company removed the offending claims.
• 2021 Oregon mislabeling incident. Curaleaf's Select-branded Oregon operation was involved in a recall after THC tinctures were reportedly mislabeled and sold as CBD, leading to hospitalizations and litigation ^[7]. The Oregon Liquor and Cannabis Commission and reporting outlets documented the recall and subsequent lawsuits.
• Securities and shareholder litigation. As with most large MSOs, Curaleaf has been named in shareholder lawsuits; current status of any litigation should be checked in the company's most recent filings rather than this article.

These incidents don't make Curaleaf uniquely bad — large operators face proportionally more scrutiny — but they do illustrate why 'big brand' should not be conflated with 'safer product.'

Availability and legal-market notes

Curaleaf-affiliated dispensaries and products are available only within state-licensed cannabis markets where the company holds active licenses. Because of US federal prohibition, cannabis products cannot legally cross state lines, so a 'Select' cartridge sold in Massachusetts and one sold in Arizona are separate state-licensed products manufactured under separate state programs, even though they share branding ^[2][8].

This means:

• Lab results, potency, and even formulation can differ state to state.
• A product available in one Curaleaf market may not exist in another.
• 'Curaleaf' hemp-derived CBD products sold online operate under a different legal framework than its state-licensed THC products and have their own labeling and quality caveats ^[6][8].

What to verify before relying on brand claims

Before trusting any specific claim about a Curaleaf or Select or Grassroots product, check:

1. Current license status with the state cannabis regulator (e.g., Massachusetts CCC, Florida OMMU, New York OCM). Licenses can be suspended, transferred, or revoked.
2. Certificate of analysis (COA) for the specific batch — potency and contaminant testing varies by lab and by state program.
3. Recall notices from state regulators and the company itself.
4. The current corporate structure, since MSOs frequently divest assets in specific states; a 'Curaleaf' store today may be a different operator next quarter.
5. Marketing claims about wellness benefits, which the FDA has previously cited Curaleaf for making without adequate evidence ^[6].

This profile was last checked in 2025. Corporate structure, brand ownership, and licensing change frequently in the cannabis industry; treat any specific claim here as a starting point for your own verification, not a final answer.

Sources

How this page was made

Related

• Trulieve Cannabis Corp. — A US multi-state cannabis operator best known for its dominant retail and cultivation foot...